The Cannabinoid Use in Progressive Inflammatory brain Disease (CUPID) trial: a randomised double-blind placebo-controlled parallel-group multicentre trial and economic evaluation of cannabinoids to slow progression in multiple sclerosis

201576 citationsJournal Articlediamond Open Access

Authors

Susan Ball · University of Plymouth

Jane Vickery · Peninsula College of Medicine and Dentistry

Jeremy Hobart · Peninsula College of Medicine and Dentistry

Dave Wright · University of Plymouth

Colin Green · University of Exeter

James Shearer · University of Exeter

Andrew Nunn ·

Abstract

The National Institute for Health Research Health Technology Assessment programme, the Medical Research Council Efficacy and Mechanism Evaluation programme, Multiple Sclerosis Society and Multiple Sclerosis Trust. The report will be published in full in Health Technology Assessment; Vol. 19, No. 12. See the NIHR Journals Library website for further project information.

Topics & Keywords

Multiple Sclerosis Research Studies Polyomavirus and related diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Health Technology Assessment

Volume 19, Issue 12, pp. 1-188

DOI: 10.3310/hta19120

Field-Weighted Citation Impact: 4.65